An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease

• Status: Withdrawn
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and tolerability of Brincidofovir (BCV) when administered as an initial 200mg dose followed by 100mg twice weekly (BIW) for a total of 5 doses.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chimerix
• Treatments: Antiviral Agents; Brincidofovir

Criteria

Inclusion Criteria:

• Positive for Ebola virus RNA in plasma

• Subject must be able to ingest, absorb, and tolerate oral medication

• Subject must be willing to use adequate contraception during their participation

Exclusion Criteria:

-